INDIVIOR PLC (INVVY)
OTC PINK OTC PINK Primary 
UK's Indivior appoints Joe Ciaffoni as CEO
British drugmaker Indivior on Thursday said it appointed Joe Ciaffoni as its new CEO, replacing current boss Mark Crossley.
Indivior PLC (INDV) Q4 2024 Earnings Call Transcript
Indivior PLC (INDV) Q4 2024 Earnings Call Transcript
European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat
Indivior Plc INDV stock plunged following the company's fiscal year 2025 guidance that fell short of Street expectations.
Indivior PLC (INDV) Q4 Earnings Meet Estimates
Indivior PLC (INDV) came out with quarterly earnings of $0.32 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.43 per share a year ago.
Indivior PLC (INDV) Q3 2024 Earnings Call Transcript
Indivior PLC (NASDAQ:INDV ) Q3 2024 Earnings Conference Call October 24, 2024 8:00 AM ET Company Participants Jason Thompson - Head, IR Mark Crossley - CEO Christian Heidbreder - Chief Scientific Officer Ryan Preblick - CFO Conference Call Participants David Amsellem - Piper Sandler Chase Knickerbocker - Craig-Hallum Paul Cudden - Deutsche Numis Christian Glennie - Stifel Operator Good day and thank you for standing by. Welcome to the Indivior PLC Third Quarter 2024 Conference Call.
Indivior PLC (INDV) Surpasses Q3 Earnings and Revenue Estimates
Indivior PLC (INDV) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.34 per share a year ago.
Indivior price target slashed after second profit warning of the year
Indivior PLC (LSE:INDV) received a sharp downgrade from investment bank Stifel, cutting its price target from 2,100p to 1,400p, following the company's second profit warning of 2024. Stifel cites rising competition from rival drug Brixadi as a key reason for lowering estimates and slashing earnings forecasts by more than 20%.
Indivior: This Value Stock Has Over 100% Upside Potential If Market Share Stabilizes In 2025
Indivior is a $970m small-cap facing to transitory headwinds resulting in extremely negative sentiment and fascinatingly low valuation. Due to the extreme mis-pricing I argue Indivior offers investors great risk/reward asymmetry with upside potential of 104% based on today's share price of $7.46. Temporary headwinds like Medicaid disenrollments, market share loses affecting Sublocade growth and ongoing antitrust litigations are priced in at a current forward EV/EBITDA of 2.3x.
Indivior plunges on profit warning as rival anti-opioid product sells faster than expected
Indivior PLC (LSE:INDV) shares dropped over 16% after the drug company warned that sales of its Sublocade long-lasting opioid addiction treatment were hit by a rise in rival generic versions. Management of the group now sees lower than expected revenue from Sublocade in the third quarter and full year from a combination of faster initial adoption of a competitor's rival long-acting injectable treatment, as well as other factors.
British drugmaker Indivior cuts 2024 revenue forecast, shares fall
British drugmaker Indivior on Thursday cut its 2024 net revenue forecast for the second time in three months, citing lower than expected revenues from its Sublocade treatment for opioid use disorder, sending shares 15% lower.
Investors in Indivior PLC Should Contact Levi & Korsinsky Before October 1, 2024 to Discuss Your Rights – INDV
NEW YORK, NY / ACCESSWIRE / October 1, 2024 / If you suffered a loss on your Indivior PLC (NASDAQ:INDV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Investors in Indivior PLC Should Contact Levi & Korsinsky Before October 1, 2024 to Discuss Your Rights - INDV
NEW YORK, NY / ACCESSWIRE / October 1, 2024 / If you suffered a loss on your Indivior PLC (NASDAQ:INDV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
